Document is current
Any future updates will be listed below
-
Authors
Troiani, Alessandro
Hung, Lingshan
Pinato, David J.
Martinez, Maria
Sarker, Debashish
Ward, Caroline
Izadi, Hooshang
Goldin, Rob
Vithayathil, Mathew
Alharbi, Sultan
Lu, Haonan
Sharma, Rohini
-
Funding
Funding for this research was provided by:
Imperial Experimental Cancer Medicine Centre
Incyte
- License Information
-
More Information
Article History
Received: 15 December 2024
Accepted: 5 January 2026
First Online: 11 February 2026
Competing interests
: R.S. received lecture fees from EISAI and Roche, travel expenses from Roche, research funding to the institution from Novartis, Boston Scientific and Terumo Europe. D.J.P. received lecture fees from Bayer Healthcare, EISAI, BMS, Roche, Boston Scientific, travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, DaVolterra, Mursla, IPSEN, Exact Sciences, Avamune, EISAI, Roche, Starpharma, LiFT biosciences and Astra Zeneca; received research funding (to institution) from MSD, GSK and BMS.
